This paper outlines a treatment protocol to run alongside of standard current treatment of
glioblastoma- resection,
temozolomide and radiation. The epithelial to mesenchymal transition (EMT) inhibiting sextet, EIS Regimen, uses the ancillary attributes of six older medicines to impede EMT during
glioblastoma. EMT is an actively motile,
therapy-resisting, low proliferation, transient state that is an integral feature of
cancers' lethality generally and of
glioblastoma specifically. It is believed to be during the EMT state that
glioblastoma's centrifugal migration occurs. EMT is also a feature of untreated
glioblastoma but is enhanced by
chemotherapy, by radiation and by surgical
trauma. EIS Regimen uses the antifungal drug
itraconazole to block Hedgehog signaling, the antidiabetes drug
metformin to block
AMP kinase (AMPK), the
analgesic drug
naproxen to block Rac1, the anti-
fibrosis drug
pirfenidone to block
transforming growth factor-beta (
TGF-beta), the psychiatric drug
quetiapine to block receptor activator NFkB
ligand (RANKL) and the
antibiotic rifampin to block Wnt- all by their previously established ancillary attributes. All these systems have been identified as triggers of EMT and worthy targets to inhibit. The EIS Regimen drugs have a good safety profile when used individually. They are not expected to have any new side effects when combined. Further studies of the EIS Regimen are needed.